Literature DB >> 24452761

[Medical therapy of heart and lung diseases. Effects on the respective other organ].

S Möhlenkamp1, G Weinreich, T Neumann, T Voshaar, H Teschler.   

Abstract

Many patients suffer from both heart and lung diseases. The choice of medical drugs should not only be driven by the clinical and prognostic effects on the target organ but should also be selected based on the effects on the respective other organ. Beta blockers and statins have both beneficial and harmful effects on the respiratory system. Angiotensin-converting enzyme (ACE) inhibitors and amiodarone can cause severe lung damage. Low-dose thiazides and calcium antagonists are first-line medications in hypertensive asthma patients but beta blockers should be avoided. Theophyline should be used with caution in patients with known cardiac disease. Glucocorticosteroids can cause cardiovascular symptoms while the phosphodiesterase inhibitor roflumilast appears to have no relevant cardiovascular side effects. Anticholinergic drugs have both favorable and unfavorable cardiovascular (side) effects. Short-acting beta-2 sympathomimetic drugs (SABA) and macrolides in particular can trigger arrhythmia and some SABAs are associated with a higher incidence of myocardial infarction. Detailed knowledge of the effects of drugs used for the treatment of lung and heart diseases on the respective other organ and the associated complications and long-term effects are essential in providing optimal medical care to the many patients who present with both respiratory and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452761     DOI: 10.1007/s00059-013-4035-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  88 in total

Review 1.  [Expert meeting chronic obstructive airway disease--cardiovascular aspects of COPD].

Authors:  J Lorenz; R Bals; H Magnussen; M Pfeifer; W Randerath; G Steinkamp; C Taube; H Teschler; C Vogelmeier; T Welte; H Worth
Journal:  Pneumologie       Date:  2013-09-02

2.  Cardiovascular risks with azithromycin and other antibacterial drugs.

Authors:  Andrew D Mosholder; Justin Mathew; John J Alexander; Harry Smith; Sumathi Nambiar
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

3.  Corticosteroids and the risk of atrial fibrillation.

Authors:  Cornelis S van der Hooft; Jan Heeringa; Guy G Brusselle; Albert Hofman; Jacqueline C M Witteman; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Arch Intern Med       Date:  2006-05-08

Review 4.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

5.  Life-threatening events after theophylline overdose: a 10-year prospective analysis.

Authors:  M Shannon
Journal:  Arch Intern Med       Date:  1999-05-10

6.  beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease.

Authors:  Mitchell J Barnett; Gary Milavetz; Peter J Kaboli
Journal:  Pharmacotherapy       Date:  2005-11       Impact factor: 4.705

7.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

Review 8.  Potential role of endogenous adenosine in ticagrelor-induced dyspnea.

Authors:  Yuly G Belchikov; Seth J Koenig; Elissa M Dipasquale
Journal:  Pharmacotherapy       Date:  2013-05-26       Impact factor: 4.705

9.  Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic.

Authors:  R S Schwartzstein; C H Fanta
Journal:  Am Rev Respir Dis       Date:  1986-08

10.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.

Authors:  Eugene Kotlyar; Anne M Keogh; Peter S Macdonald; Ruth H Arnold; Dermot J McCaffrey; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

View more
  1 in total

1.  Hydrogen-rich solution attenuates myocardial injury caused by cardiopulmonary bypass in rats via the Janus-activated kinase 2/signal transducer and activator of transcription 3 signaling pathway.

Authors:  Keyan Chen; Yingjie Sun; Yugang Diao; Tiezheng Zhang; Wanwei Dong
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.